Were any significant DXCM insider stock transactions (buys/sells) reported between June and September 2025?

Based on the available information, there were no direct reports of significant DXCM insider stock transactions (buys/sells) via Form 4 filings explicitly detailed in the search results between June and September 2025. However, Dexcom, Inc.'s Quarterly Report on Form 10-Q for the period ended June 30, 2025, indicated that two Section 16 officers and directors adopted Rule 10b5-1 trading arrangements during the three months ended June 30, 2025: * Kyle Malady (Director) adopted a trading arrangement on June 6, 2025, for 2,885 shares, with an expiration date of June 4, 2026.

• Jereme M. Sylvain (Executive Vice President, Chief Financial Officer) adopted a trading arrangement on May 27, 2025, for 12,899 shares, with an expiration date of May 27, 2026. The company stated that transactions made under these Rule 10b5-1 trading arrangements "will be disclosed publicly in Section 16 filings with the SEC". While the adoption of these plans occurred within or just before the specified period, the search results did not contain the subsequent Form 4 filings detailing any actual sales or purchases made under these plans during June, July, August, or September 2025. For a comprehensive view of all insider transactions, it would be necessary to consult Fintel's dedicated insider trading pages for DXCM, which aggregate Form 4 filings. You can find more detailed insider transaction data and related analytics on Fintel's "Latest Insider Trades" and "Insider Buy/Sell Ratios" pages for DXCM.